TNF-238A promoter polymorphism contributes to susceptibility to ankylosing spondylitis in HLA-B27 negative patients

Journal of Rheumatology

Volumn 28, Issue 6, 2001, Pages 1288-1293

  Gonzalez S ^a   Torre Alonso, J C ^a   Martinez Borra J ^a   Fernandez Sanchez J A ^a   Lopez Vazquez A ^a   Rodriguez Perez A ^a   Lopez Larrea C ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Ankylosing spondylitis; HLA B27 negative; MICA Gene; Polymorphism; Spondyloarthropathy; Tumor necrosis factor

Indexed keywords

CELL DNA; HLA B27 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HLA TYPING; HUMAN; IRIDOCYCLITIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY TESTING; HLA-B27 ANTIGEN; HUMANS; MALE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034982051     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Ankylosing spondylitis and HL-A 27
2. Spondyloarthropathies: Editorial review
3. The risk of developing ankylosing spondylitis in HLA-B27 positive individual. A comparison of relatives of spondylitis patients with the general population
4. Susceptibility to ankylosing spondylitis in twins. The role of genes, HLA, and the environment
5. Investigating the genetic basis of ankylosing spondylitis: Linkage studies with the major histocompatibility complex region
6. The HLA component of the genetic contribution to ankylosing spondylitis
7. A genome-wide screen for susceptibility loci in ankylosing spondylitis
8. A worldwide overview: The epidemiology of HLA-B27 and associated spondyloarthritides
9. The B7 cross-reactive group and spondyloarthropathies: An epidemiological approach
10. B7-CREG and ankylosing spondylitis
11. HLA-Bw60 increases susceptibility to ankylosing spondylitis in HLA-B27+patients
12. Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients
13. MaLMP2 polymorphism is associated with extraspinal disease in HLA-B27 negative Caucasian and Mexican Mestizo patients with ankylosing spondylitis
14. A second lineage of mammalian major histocompatilibility complex class I genes
15. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: A close correlation between serum IL-6 and disease activity and severity
16. Single base change in the human tumour necrosis factor alpha gene detectable by Nco I restriction of the PCR product
17. A polymorphic variation in a putative regulation box of the TNFA promoter region
18. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation
19. The -308 tumor necrosis factor alpha promoter polymorphism affects transcription
20. Low secretion of tumor necrosis factor α, but no other Th1 or Th2 cytokines by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis
21. Tumor necrosis factor gene polymorphism as severity marker in rheumatoid arthritis
22. Different transcriptional activity an in vitro TNF-α production in psoriasis patients carrying the TNF-α 238A promoter polymorphism
23. No independent association between a tumor necrosis factor-alpha promotor region polymorphism and insulin-dependent diabetes mellitus
24. Polymorphism of tumor necrosis factor-alpha at position -308 in relation to ankylosing spondylitis
25. HLA-B27 alone rather than B27-related haplotypes contributes to ankylosing spondylitis susceptibility
26. Polymorphism within the tumor necrosis factor alpha promoter region in patients with ankylosing spondylitis
27. Tumor necrosis gene polymorphisms in ankylosing spondylitis
28. Association of different tumor necrosis factor α promoter allele frequencies with ankylosing spondylitis in HLA-B27 individuals
29. The -308.1 polymorphism in the promoter region of the tumor necrosis factor gene is associated with ankylosing spondylitis independent of HLA-B27
30. The MIC-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to develop psoriatic arthritis, and is independent of the association of Cw*0602 in psoriasis
31. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria
32. Psoriatic arthritis: A clinical, immunological and radiological study of 180 patients
33. Exploración de las sacroiliacas
34. The epidemiological diagnosis of ankylosing spondylitis
35. HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis
36. Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers
37. HLA-DR typing by PCR amplification with sequence-specific primers in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation
38. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors
39. Comparison of clinical features in HLA-B27 positive and negative patients with ankylosing spondylitis
40. Genetic heterogeneity in primary ankylosing spondylitis
41. Acute anterior uveitis and spondyloarthropathies
42. Terminology, introduction, diagnostic criteria, and overview
43. The effect of HLA-DR genes on susceptibility to and severity of ankylosing spondylitis
44. Triplet repeat polymorphism in the MICA gene in HLA-B27 positive and negative Caucasian patients with ankylosing spondylitis
45. A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis
46. Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha
47. Enterobacterial infection modulates major histocompatibility complex class I expression on mononuclear cells